Solésence
Develops and manufactures mineral-UV skin-health formulations for brand partners.
Something off on this page? Send us feedback.
Profile
Supplies beauty and wellness partners with materials engineering, formulation development, and commercial manufacturing for skin-health products. Mineral-UV prestige skincare formulations with proprietary active pharmaceutical ingredients are its primary offering, alongside smaller legacy advanced-materials businesses.
Engineering materials, developing formulations, and manufacturing skin-health products for beauty and wellness brand partners are the core activities. Fully developed prestige skincare formulations with mineral UV protection and proprietary active pharmaceutical ingredients are the primary skin-health offering. Skin health is the current operating focus.
The business draws on materials-engineering capabilities that originated in nanocrystalline materials and uses them alongside formulation development and commercial manufacturing. The Solésence platform incorporates protection, prevention, and treatment technologies into daily-use products. Medical diagnostics, architectural and industrial coatings, abrasion-resistant additives, and plastics additives remain in the legacy advanced-materials category.
Company facts
Key statistics
Year to date −36.7% · Average volume (30d) 29.9K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 19, 2026Q2 FY26 | — | $0.00 | — | — | $15.3M | — | +5.34% |
| May 12, 2026Q1 FY26 | — | −$0.01 | — | — | $13.0M | — | +6.45% |
| Mar 31, 2026Q4 FY25 | — | $0.00 | — | — | $12.5M | — | +13.85% |
| Nov 11, 2025Q3 FY25 | — | −$0.02 | — | — | $14.6M | — | −8.92% |
Financial highlights
| 11 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $14.6M | $20.4M | $14.6M | $12.5M | $13.0M | $15.3M | |
| Gross profit | $3.4M | $5.9M | $3.4M | $3.4M | $3.3M | $4.7M | |
| Operating income | $256.0K | $1.9M | −$781.0K | $186.0K | −$504.0K | $121.0K | |
| Net income | $80.0K | $2.7M | −$1.1M | $163.0K | −$766.0K | −$158.0K | |
| Diluted EPS | $0.00 | $0.04 | −$0.02 | $0.00 | −$0.01 | −$0.00 | |
| Gross margin | 23.1% | 28.9% | 23.1% | 27.4% | 25.7% | 31.0% | |
| Operating margin | 1.8% | 9.4% | -5.4% | 1.5% | -3.9% | 0.8% |
Fiscal years (4-quarter sums)FY24 $52.3M · FY25 $62.1M
Revenue by product · Q2 FY26
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $1.0M · Total debt $22.7M · Total assets $46.4M · Shareholders' equity $13.2M
Dividends
No dividends on record.
Ownership
Shares outstanding 70.63M · Float 18.32M · 25.9% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Whitmore Bradford T · 10 percent owner | 18.67M | 26.43% | Form 4 | Jun 2, 2025 |
| R. Janet Whitmore · director | 2.09M | 2.95% | Form 4 | Dec 30, 2025 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Dec 24, 2025 | R. Janet Whitmore | director | +2,500 | $1.91 |
| Nov 14, 2025 | R. Janet Whitmore | director | +19,789 | $1.73 |
| Nov 17, 2025 | R. Janet Whitmore | director | +5,000 | $1.87 |
| Nov 18, 2025 | R. Janet Whitmore | director | +267 | $1.83 |
| Nov 19, 2025 | R. Janet Whitmore | director | +10,000 | $1.92 |
Peers
Not reported.